Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Patients must have ADHD.

• Must be 13-16 years of age.

• Must be able to swallow capsules.

• Expected to achieve score of 70 or more on IQ test

• Willing and reliable to keep appts. for clinic visits and test

Exclusion Criteria:

• Treatment within last 30 days with a drug that has not received regulatory approval for any indication.

• Patients who weigh less than 40 kg or greater than 70 kg.

• Patients with documented history of Bipolar I or II disorder, or psychosis

• Patients with documented history of autism, asperger's syndrome or pervasive developmental disorder